Latest news with #RecursionPharmaceuticals
Yahoo
a day ago
- Business
- Yahoo
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
Key Points Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 stocks we like better than Recursion Pharmaceuticals › Before market open on Tuesday, Recursion Pharmaceuticals (NASDAQ: RXRX) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market. The company's stock ended up closing the day almost 5% lower in price, a steeper fall than the 0.5% dip of the benchmark S&P 500 index. Second quarter: revenue rose, but net loss deepened For its second quarter, Recursion earned $19.2 million in revenue, which was up from the slightly more than $14.4 million in the same period of 2024. However, the clinical-stage biotech company's generally accepted accounting principles (GAAP) net loss deepened considerably, coming in at almost $172 million ($0.41) against the $97.5 million deficit in the year-ago period. Although analysts tracking the stock were collectively modeling a lower revenue figure of $15.4 million, their net loss estimate was considerably narrower, at $0.35 per share. Recursion, which targets cancer and rare disorders with its investigational drugs, provided an update on its pipeline. The most advanced of its programs, oncology drug REC-617, advanced into a phase 1/2 clinical trial in the first half of the year. Teaming up As a biotech without a product currently on pharmacy shelves, Recursion generates modest revenue largely from collaborations with large pharmaceutical companies. Among these well-known mainstays are Bayer and Merck. In the earnings release, it updated the status of several of these; an especially promising one now is a tie-up with Sanofi, which has the potential to produce more than $300 million in milestone payments. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Tanked on Tuesday was originally published by The Motley Fool
Globe and Mail
3 days ago
- Business
- Globe and Mail
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
Key Points Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 stocks we like better than Recursion Pharmaceuticals › Before market open on Tuesday, Recursion Pharmaceuticals (NASDAQ: RXRX) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers clearly didn't impress the market. The company's stock ended up closing the day almost 5% lower in price, a steeper fall than the 0.5% dip of the benchmark S&P 500 index. Second quarter: revenue rose, but net loss deepened For its second quarter, Recursion earned $19.2 million in revenue, which was up from the slightly more than $14.4 million in the same period of 2024. However, the clinical-stage biotech company's generally accepted accounting principles (GAAP) net loss deepened considerably, coming in at almost $172 million ($0.41) against the $97.5 million deficit in the year-ago period. Although analysts tracking the stock were collectively modeling a lower revenue figure of $15.4 million, their net loss estimate was considerably narrower, at $0.35 per share. Recursion, which targets cancer and rare disorders with its investigational drugs, provided an update on its pipeline. The most advanced of its programs, oncology drug REC-617, advanced into a phase 1/2 clinical trial in the first half of the year. Teaming up As a biotech without a product currently on pharmacy shelves, Recursion generates modest revenue largely from collaborations with large pharmaceutical companies. Among these well-known mainstays are Bayer and Merck. In the earnings release, it updated the status of several of these; an especially promising one now is a tie-up with Sanofi, which has the potential to produce more than $300 million in milestone payments. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Yahoo
6 days ago
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month
Recursion Pharmaceuticals experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company's stock movement appeared isolated from these wider trends, which implies internal factors or developments might have played a part, although specific catalysts weren't highlighted during this period. This performance is noteworthy given the current market's overall downward trend of 2.7%. We've identified 3 possible red flags for Recursion Pharmaceuticals (1 is potentially serious) that you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Recursion Pharmaceuticals' recent 9% monthly share price increase amidst broader market declines may suggest that internal developments, rather than external factors, are influencing investor sentiment. Over the past year, however, the company's total shareholder return was a decline of 19.09%, highlighting a contrast to the short-term positive movement. Comparatively, RXRX underperformed the US Biotechs industry, which saw an 8.4% decline over the same period, and also lagged behind the US market return of 17.7%. The heightened interest in the stock could be linked to enthusiasm around its AI-driven drug discovery programs, including REC-617 and REC-994 trials, which suggest potential future revenue growth. Yet, Recursion's lack of profitability and reliance on successful trial outcomes may introduce uncertainty into earnings forecasts. The company's expected revenue growth of 39.9% annually for the next three years could be influenced by the new developments and partnerships, possibly providing support to the optimistic forecasts. The current share price of US$5.68 remains below the consensus analyst price target of US$7.14, indicating a potential upside of 25.7%. This price target reflects expectations of significant future revenue and earnings improvements. However, analysts' forecasts include assumptions such as increased profit margins and successful translation of ongoing projects into commercial revenues, underscoring the importance of navigating the risks and uncertainties outlined in their analysis. Investors may need to weigh these factors carefully when considering the company's ability to meet future targets. Evaluate Recursion Pharmaceuticals' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month
Recursion Pharmaceuticals experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company's stock movement appeared isolated from these wider trends, which implies internal factors or developments might have played a part, although specific catalysts weren't highlighted during this period. This performance is noteworthy given the current market's overall downward trend of 2.7%. We've identified 3 possible red flags for Recursion Pharmaceuticals (1 is potentially serious) that you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Recursion Pharmaceuticals' recent 9% monthly share price increase amidst broader market declines may suggest that internal developments, rather than external factors, are influencing investor sentiment. Over the past year, however, the company's total shareholder return was a decline of 19.09%, highlighting a contrast to the short-term positive movement. Comparatively, RXRX underperformed the US Biotechs industry, which saw an 8.4% decline over the same period, and also lagged behind the US market return of 17.7%. The heightened interest in the stock could be linked to enthusiasm around its AI-driven drug discovery programs, including REC-617 and REC-994 trials, which suggest potential future revenue growth. Yet, Recursion's lack of profitability and reliance on successful trial outcomes may introduce uncertainty into earnings forecasts. The company's expected revenue growth of 39.9% annually for the next three years could be influenced by the new developments and partnerships, possibly providing support to the optimistic forecasts. The current share price of US$5.68 remains below the consensus analyst price target of US$7.14, indicating a potential upside of 25.7%. This price target reflects expectations of significant future revenue and earnings improvements. However, analysts' forecasts include assumptions such as increased profit margins and successful translation of ongoing projects into commercial revenues, underscoring the importance of navigating the risks and uncertainties outlined in their analysis. Investors may need to weigh these factors carefully when considering the company's ability to meet future targets. Evaluate Recursion Pharmaceuticals' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
30-07-2025
- Business
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.95, moving -5.71% from the previous trading session. This change lagged the S&P 500's 0.3% loss on the day. On the other hand, the Dow registered a loss of 0.46%, and the technology-centric Nasdaq decreased by 0.38%. Heading into today, shares of the biotechnology company had gained 24.7% over the past month, outpacing the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64%. The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.35 per share. This would mark year-over-year growth of 12.5%. In the meantime, our current consensus estimate forecasts the revenue to be $14.38 million, indicating a 0.3% decline compared to the corresponding quarter of the prior year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.35 per share and revenue of $68.39 million, indicating changes of +20.12% and +16.23%, respectively, compared to the previous year. Any recent changes to analyst estimates for Recursion Pharmaceuticals should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 0.75% lower. Right now, Recursion Pharmaceuticals possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
